Targeting the MEK and STAT3 Pathways in Combination With PD1 Blockade Immunotherapy in KRAS-mutant Pancreatic Cancer

被引：0

作者：

Mehra, S. ^{[1
]}

Lamichhane, P. ^{[1
,2
]}

Messaggio, F. ^{[1
]}

Dai, X. ^{[1
]}

Dosch, A. ^{[1
]}

Willobee, B. ^{[1
]}

Srinivasan, S. ^{[1
]}

VanSaun, M. N. ^{[1
,3
]}

Nagathihalli, N. ^{[1
,3
]}

Merchant, N. ^{[1
,3
]}

机构：

[1] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA

[2] LECOM Sch Dent Med, Bradenton, FL USA

[3] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA

来源：

PANCREAS | 2019年 / 48卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1490 / 1490

页数：1

共 50 条

[41] Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
Gu, Tingxuan
Tian, Xueli
Wang, Yuanyuan
Yang, Wenqian
Li, Wenwen
Song, Mengqiu
Zhao, Ran
Wang, Mengqiao
Gao, Quanli
Li, Tiepeng
Zhang, Chengjuan
Kundu, Joydeb Kumar
Liu, Kangdong
Dong, Zigang
Lee, Mee-Hyun
FRONTIERS IN IMMUNOLOGY, 2023, 14
[42] Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Daixi Ren
Yuze Hua
Boyao Yu
Xin Ye
Ziheng He
Chunwei Li
Jie Wang
Yongzhen Mo
Xiaoxu Wei
Yunhua Chen
Yujuan Zhou
Qianjin Liao
Hui Wang
Bo Xiang
Ming Zhou
Xiaoling Li
Guiyuan Li
Yong Li
Zhaoyang Zeng
Wei Xiong
Molecular Cancer, 19
[43] Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Ren, Daixi
Hua, Yuze
Yu, Boyao
Ye, Xin
He, Ziheng
Li, Chunwei
Wang, Jie
Mo, Yongzhen
Wei, Xiaoxu
Chen, Yunhua
Zhou, Yujuan
Liao, Qianjin
Wang, Hui
Xiang, Bo
Zhou, Ming
Li, Xiaoling
Li, Guiyuan
Li, Yong
Zeng, Zhaoyang
Xiong, Wei
MOLECULAR CANCER, 2020, 19 (01)
[44] PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer
Su, Shengchen
You, Sungyong
Wang, Yanping
Tamukong, Patrick
Grasso, Catherine S.
Kim, Hyung L.
CANCER RESEARCH, 2022, 82 (12)
[45] A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC).
Hosein, Peter Joel
Datta, Jashodeep
Ezenwajiaku, Nkiruka
Zhou, Zhiqun
Yow, Maria V.
Boone, Melinda
Nagathihalli, Nagaraj
Reis, Isildinha M.
Merchant, Nipun B.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS713 - TPS713
[46] Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas
Donald Lawrence
Victoria Atkinson
Sachin Agarwal
Wilson H. Miller
Matteo S. Carlino
Rosalie Fisher
Georgina V. Long
F. Stephen Hodi
Jennifer Tsoi
Catherine S. Grasso
Bijoyesh Mookerjee
Qing Zhao
Razi Ghori
Blanca Homet Moreno
Nageatte Ibrahim
Omid Hamid
Nature Medicine, 2019, 25 : 936 - 940
[47] Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Ribas, Antoni
Lawrence, Donald
Atkinson, Victoria
Agarwal, Sachin
Miller, Wilson H., Jr.
Carlino, Matteo S.
Fisher, Rosalie
Long, Georgina V.
Hodi, F. Stephen
Tsoi, Jennifer
Grasso, Catherine S.
Mookerjee, Bijoyesh
Zhao, Qing
Ghori, Razi
Moreno, Blanca Homet
Ibrahim, Nageatte
Hamid, Omid
NATURE MEDICINE, 2019, 25 (06) : 936 - +
[48] Targeting STAT3 by a small molecule suppresses pancreatic cancer progression
Chen, Huang
Bian, Aiwu
Yang, Lian-fang
Yin, Xuan
Wang, Jie
Ti, Chaowen
Miao, Ying
Peng, Shihong
Xu, Shifen
Liu, Mingyao
Qiu, Wen-Wei
Yi, Zhengfang
ONCOGENE, 2021, 40 (08) : 1440 - 1457
[49] Targeting of cancer associated fibroblast-specific MEK1 and STAT3 to overcome immunosuppressive microenvironment in Pancreatic Ductal Adenocarcinoma (PDAC).
Mehra, Siddharth
Dai, Xizi
Bianchi, Anna
Dosch, Austin
Silva, Iago de Castro
Sharma, Prateek
Singh, Samara
Srinivasan, Supriya
Nagathihalli, Nagaraj
Datta, Jashodeep
Merchant, Nipun
CANCER RESEARCH, 2020, 80 (22)
[50] Two Is Better Than One: Combining IGF1R and MEK Blockade as a Promising Novel Treatment Strategy Against KRAS-Mutant Lung Cancer
Chen, Ron
Sweet-Cordero, E. Alejandro
CANCER DISCOVERY, 2013, 3 (05) : 491 - 493

← 1 2 3 4 5 →